PD-1 blockade does not enhance alloimmunization after allogeneic dendritic cell vaccination in cancer patients
BackgroundBlocking programmed cell death protein 1 (PD-1) has become a standard cancer immunotherapy, increasingly used in kidney, liver, or heart transplant recipients who develop skin cancer or hepatocellular carcinoma, despite the increased risk of …